{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:49:50Z","timestamp":1754153390995,"version":"3.41.2"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1111\/igc.0b013e3181a1a6c9","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T13:30:18Z","timestamp":1291383018000},"page":"447-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Attitudes Regarding the Use of Hematopoietic Colony-Stimulating Factors and Maintenance of Relative Dose Intensity Among Gynecologic Oncologists"],"prefix":"10.1016","volume":"19","author":[{"given":"Angeles Alvarez","family":"Secord","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Bae-Jump","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Calingaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Clarke-Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Soper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola A.","family":"Gehrig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines","author":"Ozer","year":"2000","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2006.06.4451","article-title":"update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","author":"Smith","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0015","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1200\/JCO.1994.12.11.2471","volume":"12","year":"1994","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0020","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1200\/JCO.1996.14.6.1957","volume":"14","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0025","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Myeloid Growth Factors. v.1.2007. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloid_growth.pdf. 2007."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0030","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.1996.14.9.2511","article-title":"Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey","volume":"14","author":"Bennett","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0035","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.1999.17.11.3676","article-title":"Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines","volume":"17","author":"Bennett","year":"1999","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1634\/theoncologist.3-5-365","article-title":"The importance of planned dose of chemotherapy on time: do we need to change our clinical practice?","volume":"3","author":"Foote","year":"1998","journal-title":"Oncologist."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0045","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/1097-0142(20010915)92:6<1354::AID-CNCR1458>3.0.CO;2-P","article-title":"Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care","volume":"92","author":"Link","year":"2001","journal-title":"Cancer."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0050","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000282728","article-title":"The importance of dose intensity in chemotherapy of advanced testicular cancer","volume":"54","author":"Miyanaga","year":"1995","journal-title":"Urol Int."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0055","first-page":"901","article-title":"Cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. New Engl","volume":"332","author":"Bonadonna","year":"1994","journal-title":"J Med."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0060","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/oxfordjournals.annonc.a058619","article-title":"Prognostic-significance of received relative dose intensity in non-Hodgkins lymphoma patients: application to LNH-87 protocol. The GELA (Groupe d\u2019Etude des Lymphomes de l\u2019Adulte)","volume":"4","author":"Lepage","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0065","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0959-8049(03)00152-7","article-title":"Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients: 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin","volume":"39","author":"Dittrich","year":"2003","journal-title":"Eur J Cancer."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0070","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/oxfordjournals.annonc.a058516","article-title":"A randomized dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles","volume":"4","author":"Murphy","year":"1993","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0075","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1200\/JCO.2003.10.082","article-title":"Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study","volume":"21","author":"Omura","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0080","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.1995.13.7.1589","article-title":"Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study","volume":"13","author":"McGuire","year":"1995","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0085","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.1997.15.1.193","article-title":"Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study","volume":"15","author":"Jakobsen","year":"1997","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0090","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1200\/JCO.2006.09.7527","article-title":"Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar\/AIO and EBMT","volume":"25","author":"M\u00f6bus","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1200\/JCO.1996.14.2.351","article-title":"High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest","volume":"14","author":"Conte","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0100","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.1998.16.7.2426","article-title":"Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group","volume":"16","author":"Gore","year":"1998","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0140-6736(92)91404-V","article-title":"Randomized study of 2 doses of cisplatin with cyclophosphamide in epithelial ovarian cancer","volume":"340","author":"Kaye","year":"1992","journal-title":"Lancet."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0110","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1200\/JCO.1996.14.7.2113","article-title":"Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer","volume":"14","author":"Kaye","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000238673","article-title":"A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer","volume":"35","author":"Ngan","year":"1989","journal-title":"Chemotherapy."},{"key":"10.1111\/IGC.0b013e3181a1a6c9_bb0120","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1997.15.4.1291","article-title":"Dose-intensity in ovarian carcinoma: hold, enough?","volume":"15","author":"Thigpen","year":"1997","journal-title":"J Clin Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181a1a6c9","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24027129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24027129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1111\/IGC.0b013e3181a1a6c9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:07:57Z","timestamp":1753232877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24027129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S1048891X24027129"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181a1a6c9","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attitudes Regarding the Use of Hematopoietic Colony-Stimulating Factors and Maintenance of Relative Dose Intensity Among Gynecologic Oncologists","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181a1a6c9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 IGCS and ESGO","name":"copyright","label":"Copyright"}]}}